Summit Therapeutics opens global Phase II trial of ivonescimab in advanced clear cell renal cell carcinoma

Summit Therapeutics announced the opening of its global Phase II SMT112-216 trial of ivonescimab alone or combined with cadonilimab or ipilimumab in previously untreated advanced clear cell renal cell carcinoma.

Detected & updated continuously · Source: Nebula